Metrics to compare | POLB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | −1.4x | −0.5x | |
PEG Ratio | −0.57 | −0.02 | 0.00 | |
Price/Book | 6.5x | 1.8x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.0x | |
Upside (Analyst Target) | 120.9% | 209.8% | 58.6% | |
Fair Value Upside | Unlock | 11.6% | 10.2% | Unlock |
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.